110 related articles for article (PubMed ID: 23086510)
1. Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin.
Desai A; Telang GH; Olszewski AJ
Ann Hematol; 2013 Apr; 92(4):567-8. PubMed ID: 23086510
[No Abstract] [Full Text] [Related]
2. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
[TBL] [Abstract][Full Text] [Related]
3. [Long-term administration of brentuximab vedotin in a patient with primary cutaneous anaplastic large cell lymphoma with peripheral blood involvement with leukemic change].
Kumekawa H; Mizuchi D; Iiyama M
Rinsho Ketsueki; 2018; 59(2):187-190. PubMed ID: 29515072
[TBL] [Abstract][Full Text] [Related]
4. Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine.
Poon LM; Kwong YL
Ann Hematol; 2016 Apr; 95(5):847-9. PubMed ID: 26931114
[No Abstract] [Full Text] [Related]
5. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
[TBL] [Abstract][Full Text] [Related]
6. Remission of refractory granulomatous primary cutaneous anaplastic large cell lymphoma to brentuximab vedotin.
Sasapu A; Dunn ALJ; Gardner J; Wong HK
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34290015
[TBL] [Abstract][Full Text] [Related]
7. Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy.
Onaka T; Kitagawa T; Kawakami C; Yonezawa A
Turk J Haematol; 2018 May; 35(2):135-136. PubMed ID: 29391331
[No Abstract] [Full Text] [Related]
8. Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.
Patsinakidis N; Kreuter A; Moritz RK; Stücker M; Altmeyer P; Möllenhoff K
Acta Derm Venereol; 2015 Feb; 95(2):233-4. PubMed ID: 24733422
[No Abstract] [Full Text] [Related]
9. Multifocal primary cutaneous CD30+ anaplastic large cell lymphoma responsive to thalidomide: the molecular mechanism and the clinical application.
Lee JH; Cheng AL; Lin CW; Kuo SH
Br J Dermatol; 2009 Apr; 160(4):887-9. PubMed ID: 19222454
[No Abstract] [Full Text] [Related]
10. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
11. RF - Brentuximab as Treatment for CD30
Morgado-Carrasco D; Combalia A; Estrach Panella T
Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
[No Abstract] [Full Text] [Related]
12. Complete healing of basal cell carcinoma under bendamustine and brentuximab vedotin therapy in a patient with cutaneous lymphoma.
Baykal C; Kutlay A; Buyukbabani N
Dermatol Ther; 2019 Jul; 32(4):e12934. PubMed ID: 30977947
[No Abstract] [Full Text] [Related]
13. Primary cutaneous anaplastic large cell lymphoma successfully treated with low-dose oral methotrexate.
Fujita H; Nagatani T; Miyazawa M; Wada H; Koiwa K; Komatsu H; Ikezawa Z
Eur J Dermatol; 2008; 18(3):360-1. PubMed ID: 18474486
[No Abstract] [Full Text] [Related]
14. Brentuximab vedotin in CD30
Enos TH; Feigenbaum LS; Wickless HW
Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Vinblastine in Primary Cutaneous Anaplastic Large Cell Lymphoma.
Laly P; Ingen-Housz-Oro S; Beylot-Barry M; Verneuil L; Adamski H; Brice P; Bagot M
JAMA Dermatol; 2015 Sep; 151(9):1030-1. PubMed ID: 26108120
[No Abstract] [Full Text] [Related]
16. Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.
Federico M; Luminari S; Pellegrini C; Merli F; Pesce EA; Chauvie S; Gandolfi L; Capodanno I; Salati M; Argnani L; Zinzani PL
Haematologica; 2016 Apr; 101(4):e139-41. PubMed ID: 26703964
[No Abstract] [Full Text] [Related]
17. Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy.
Aguiar-Bujanda D; Dueñas-Comino A; Cabello C; Bastida J; Rivero-Vera JC; Limeres-González MA
Eur J Dermatol; 2017 Dec; 27(6):671-673. PubMed ID: 29165301
[No Abstract] [Full Text] [Related]
18. Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox.
Dao H; Barr PM; Honda K
J Am Acad Dermatol; 2011 Jun; 64(6):e123-5. PubMed ID: 21571160
[No Abstract] [Full Text] [Related]
19. Primary cutaneous aggressive epidermotropic cytotoxic CD8
Cyrenne BM; Subtil A; Girardi M; Foss F
Int J Dermatol; 2017 Dec; 56(12):1448-1450. PubMed ID: 29047111
[No Abstract] [Full Text] [Related]
20. Brentuximab vedotin for the treatment of CD30+ lymphomas.
Foyil KV; Bartlett NL
Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
